7. Why is an IMI public-private partnership needed to do this?

In order to develop an agreed, scientifically robust, and clinically relevant condition of risk as the proposed PF&S, it is necessary that all the major stakeholders involved in the prevention and care of the older persons (e.g., academia, pharmaceutical industries, experts in bioethics, public health economists, patients' representatives) might provide their expertise and recommendations. Only through a close collaboration between public and private partners will allow the production of results that are not only scientifically robust, but also pave the way for the future clinical implementation (in everyday medical practice) and the development of innovative pharmacological/biological treatments.